EGFR and non-small cell lung carcinoma: However, there was still a lack of economic evaluations on EGFR-TKI in the adjuvant setting, making this study the first cost-effectiveness analysis to comprehensively evaluate the benefit of adjuvant EGFR-TKI therapy for early-stage EGFR-mutant NSCLC patients.